FDA Approves Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules CII with Abuse-Deterrent Properties for the Management of Pain
Friday, August 19, 2016 -- Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | Oxycodone | OxyContin | Pain | Pain Management | Pfizer | Substance Abuse